A unique sars-cov-2 spike protein p681h variant detected in Israel

on behalf of the Israel National Consortium for SARS-CoV-2 Sequencing

doi:10.3390/vaccines9060616

A unique sars-cov-2 spike protein p681h variant detected in Israel

on behalf of the Israel National Consortium for SARS-CoV-2 Sequencing

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

The routine detection, surveillance, and reporting of novel SARS-CoV-2 variants is crucial, as these threaten to hinder global vaccination efforts. Herein we report a novel local variant with a non-synonymous mutation in the spike (S) protein P681H. This local Israeli variant was not associated with a higher infection rate or higher prevalence. Furthermore, the local variant was successfully neutralized by sera from fully vaccinated individuals at a comparable level to the B.1.1.7 variant and an Israel wild-type strain. While it is not a variant of concern, routine monitoring by sequencing is still required.

Original language	English
Article number	616
Journal	Vaccines
Volume	9
Issue number	6
DOIs	https://doi.org/10.3390/vaccines9060616
State	Published - Jun 2021

Keywords

Covid-19
SARS-CoV-2
Sequencing
Variant of concern
Virus neutralization

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/vaccines9060616

Cite this

@article{e88efdb9b1a04a5087bd969a2da9b0f8,

title = "A unique sars-cov-2 spike protein p681h variant detected in Israel",

abstract = "The routine detection, surveillance, and reporting of novel SARS-CoV-2 variants is crucial, as these threaten to hinder global vaccination efforts. Herein we report a novel local variant with a non-synonymous mutation in the spike (S) protein P681H. This local Israeli variant was not associated with a higher infection rate or higher prevalence. Furthermore, the local variant was successfully neutralized by sera from fully vaccinated individuals at a comparable level to the B.1.1.7 variant and an Israel wild-type strain. While it is not a variant of concern, routine monitoring by sequencing is still required.",

keywords = "Covid-19, SARS-CoV-2, Sequencing, Variant of concern, Virus neutralization",

author = "\{on behalf of the Israel National Consortium for SARS-CoV-2 Sequencing\} and Zuckerman, \{Neta S.\} and Shay Fleishon and Efrat Bucris and Dana Bar-Ilan and Michal Linial and Itay Bar-Or and Victoria Indenbaum and Merav Weil and Yaniv Lustig and Ella Mendelson and Michal Mandelboim and Orna Mor and Neta Zuckerman",

note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = jun,

doi = "10.3390/vaccines9060616",

language = "אנגלית",

volume = "9",

journal = "Vaccines",

issn = "2076-393X",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "6",

}

TY - JOUR

T1 - A unique sars-cov-2 spike protein p681h variant detected in Israel

AU - on behalf of the Israel National Consortium for SARS-CoV-2 Sequencing

AU - Zuckerman, Neta S.

AU - Fleishon, Shay

AU - Bucris, Efrat

AU - Bar-Ilan, Dana

AU - Linial, Michal

AU - Bar-Or, Itay

AU - Indenbaum, Victoria

AU - Weil, Merav

AU - Lustig, Yaniv

AU - Mendelson, Ella

AU - Mandelboim, Michal

AU - Mor, Orna

AU - Zuckerman, Neta

PY - 2021/6

Y1 - 2021/6

N2 - The routine detection, surveillance, and reporting of novel SARS-CoV-2 variants is crucial, as these threaten to hinder global vaccination efforts. Herein we report a novel local variant with a non-synonymous mutation in the spike (S) protein P681H. This local Israeli variant was not associated with a higher infection rate or higher prevalence. Furthermore, the local variant was successfully neutralized by sera from fully vaccinated individuals at a comparable level to the B.1.1.7 variant and an Israel wild-type strain. While it is not a variant of concern, routine monitoring by sequencing is still required.

AB - The routine detection, surveillance, and reporting of novel SARS-CoV-2 variants is crucial, as these threaten to hinder global vaccination efforts. Herein we report a novel local variant with a non-synonymous mutation in the spike (S) protein P681H. This local Israeli variant was not associated with a higher infection rate or higher prevalence. Furthermore, the local variant was successfully neutralized by sera from fully vaccinated individuals at a comparable level to the B.1.1.7 variant and an Israel wild-type strain. While it is not a variant of concern, routine monitoring by sequencing is still required.

KW - Covid-19

KW - SARS-CoV-2

KW - Sequencing

KW - Variant of concern

KW - Virus neutralization

UR - https://www.scopus.com/pages/publications/85108332025

U2 - 10.3390/vaccines9060616

DO - 10.3390/vaccines9060616

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 34201088

AN - SCOPUS:85108332025

SN - 2076-393X

VL - 9

JO - Vaccines

JF - Vaccines

IS - 6

M1 - 616

ER -

A unique sars-cov-2 spike protein p681h variant detected in Israel

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this